Oncology Central

Lung cancer combination doubles 12-month PFS

Results from the Phase III IMpower150 study have demonstrated that the combination of atezolizumab and bevacizumab plus chemotherapy provides a significant and clinically meaningful reduction in the risk of disease worsening or death compared to bevacizumab plus chemotherapy in the first-line treatment of people with advanced non-squamous non-small-cell lung cancer (NSCLC).

Sandra Horning, Roche’s head of global product development, commented “This…study is the first positive Phase III combination trial that showed a cancer immunotherapy reduced the risk of the disease getting worse when used as an initial treatment in a broad group of individuals with advanced non-squamous NSCLC.” Horning added: “We will submit these results to regulatory authorities around the world to potentially bring a new standard of care to people living with this disease as soon as possible.”

In the study, 1202 individuals with stage IV non-squamous NSCLC who had not been treated with chemotherapy for their advanced disease were randomized to receive atezolizumab plus carboplatin and paclitaxel, atezolizumab and bevacizumab plus carboplatin and paclitaxel or bevacizumab plus carboplatin and paclitaxel.

The trial’s co-primary endpoints were progression-free survival (PFS) and overall survival (OS), with the analysis of the former goal only statistically powered to demonstrate a comparison between patients who received atezolizumab and bevacizumab plus carboplatin and paclitaxel and those given bevacizumab plus carboplatin and paclitaxel.

Key results include:

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.